HC Wainwright Reaffirms “Buy” Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 84.33% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Finally, Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Price Performance

TLX stock opened at $10.85 on Wednesday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The business has a 50-day moving average price of $11.16 and a 200 day moving average price of $9.87. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $12.48.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC grew its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Portland Investment Counsel Inc. lifted its position in shares of Telix Pharmaceuticals by 108.0% during the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after buying an additional 138,200 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Telix Pharmaceuticals during the third quarter valued at about $1,883,000. Private Advisor Group LLC boosted its holdings in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.